Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00328120
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT00313170
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 143
- Registration Number
- NCT00305448
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Faslodex in McCune-Albright Syndrome
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00278915
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00274469
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2007-02-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT00272740
- Locations
- 🇨🇭
Research Site, St.Gallen, Switzerland
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259090
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00256698
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 750
- Registration Number
- NCT00253422
- Locations
- 🇬🇧
Royal Marsden - London, London, England, United Kingdom
🇬🇧Institute of Cancer Research - Sutton, Sutton, England, United Kingdom
Fulvestrant in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00244998
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.